[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-carcinoma-of-cervix\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-carcinoma-of-cervix":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100626418",false,"NCT07435376","Intra-lesional Tumor Boost for Bulky Cervical Cancer","A Prospective Phase 2 Clinical Trial of Intra-lesional Cervical Tumor Boost for Bulky Cervical Cancer","INTLECTUAL","Inclusion Criteria:\n\n* Patients with histologically confirmed squamous cell carcinoma of the cervix.\n* Patients with bulky primary tumor, defined as a tumor volume ≥ 60 cc OR a maximum diameter ≥ 6 cm.\n* Patients aged 19 to 80 years at the time of diagnosis.\n* Patients with an ECOG performance status of 0 to 2.\n* Patients who have voluntarily agreed to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosis of other malignancies within 5 years prior to enrollment (Exceptions: carcinoma in situ of the breast and thyroid cancer).\n* Patients who are medically unfit for definitive concurrent chemoradiotherapy.\n* Patients who have received prior chemotherapy (neoadjuvant chemotherapy) before radiation therapy.\n* Patients with prior history of radiation therapy to the abdomen or pelvis.\n* Patients unable to provide informed consent due to mental or physical disabilities.","FEMALE","19 Years","80 Years",{"count":20,"type":21},17,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\n* Does the extra radiation boost effectively reduce the tumor size before the internal radiation (brachytherapy) treatment begins?\n* What medical problems (side effects) do participants have when receiving this treatment?\n\nResearchers will give this intra-lesional boost to all participants during their standard radiation therapy to see if it helps shrink the tumor more than usual.\n\nParticipants will:\n\n* Receive radiation therapy to the pelvis with a targeted boost to the tumor for about 5 to 6 weeks\n* Visit the clinic daily for radiation treatment and regularly for checkups Have an MRI scan during the 4th or 5th week of treatment to measure the tumor size\n* Receive internal radiation therapy (brachytherapy) after finishing the external radiation\n* Visit the clinic for follow-up checkups and tests for up to 2 years",[27,28],"Cervical Cancer","Squamous Cell Carcinoma of Cervix",[30,31,32,33,34,35,36,37],"cervical cancer","bulky cervical cancer","squamous cell carcinoma","intra lesional boost","simultaneous integrated boost","imrt","radiotherapy","tumor volume reduction","RECRUITING","2026-02-20",{"date":41,"type":42},"2026-02-27","ACTUAL",{"date":44,"type":42},"2025-02-23",{"date":46,"type":21},"2028-11-30",{"name":48,"class":49},"Seoul National University Bundang Hospital","OTHER",""]